Skip to main content

Terns Pharmaceuticals, Inc.

corporate_fare Company Profile

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed TERN - Latest Insights

TERN
Apr 27, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
9
TERN
Apr 27, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
TERN
Apr 24, 2026, 8:11 AM EDT
Filing Type: SC 14D9/A
Importance Score:
8
TERN
Apr 24, 2026, 7:30 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
TERN
Apr 07, 2026, 7:44 AM EDT
Filing Type: SC 14D9
Importance Score:
9
TERN
Apr 07, 2026, 7:00 AM EDT
Filing Type: SC TO-T
Importance Score:
10
TERN
Mar 25, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
10
TERN
Mar 25, 2026, 6:48 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
TERN
Jan 22, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
TERN
Jan 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
TERN
Jan 06, 2026, 8:26 PM EST
Filing Type: 4
Importance Score:
7